Business Description
Genfit SA
ISIN : US3722791098
Share Class Description:
FRA:XUPB: ADRTotal Employee Number:
192Compare
Compare
Traded in other countries / regions
GNFT.France0QT6.UKXUP.GermanyGNFTF.USA IPO Date
2020-11-03Description
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.67 | |||||
Equity-to-Asset | -0.14 | |||||
Debt-to-Equity | -6.69 | |||||
Debt-to-EBITDA | -1.81 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.78 | |||||
Beneish M-Score | 3.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 47.8 | |||||
3-Year EBITDA Growth Rate | -67.8 | |||||
3-Year EPS without NRI Growth Rate | -52.9 | |||||
3-Year FCF Growth Rate | 25.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 27.38 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.79 | |||||
9-Day RSI | 75.91 | |||||
14-Day RSI | 72.21 | |||||
3-1 Month Momentum % | 50 | |||||
6-1 Month Momentum % | 57.41 | |||||
12-1 Month Momentum % | 50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2 | |||||
Quick Ratio | 2 | |||||
Cash Ratio | 1.4 | |||||
Days Inventory | 4.83 | |||||
Days Sales Outstanding | 131.13 | |||||
Days Payable | 17458.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -11.85 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.54 | |||||
Operating Margin % | -81.86 | |||||
Net Margin % | -131.38 | |||||
EBITDA Margin % | -127.53 | |||||
FCF Margin % | -45.33 | |||||
OCF Margin % | -40.1 | |||||
ROE % | -260.09 | |||||
ROA % | -48.92 | |||||
ROIC % | -61.14 | |||||
3-Year ROIIC % | 162.64 | |||||
ROC (Joel Greenblatt) % | -430.61 | |||||
ROCE % | -75.68 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.04 | |||||
PS Ratio | 10.25 | |||||
EV-to-EBIT | -8.49 | |||||
EV-to-EBITDA | -8.67 | |||||
EV-to-Revenue | 11.06 | |||||
EV-to-Forward-Revenue | 3.55 | |||||
EV-to-FCF | -24.4 | |||||
Price-to-GF-Value | 1.53 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
Earnings Yield (Greenblatt) % | -11.78 | |||||
FCF Yield % | -4.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genfit SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 65.434 | ||
| EPS (TTM) (€) | -0.2 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.87 | ||
| Volatility % | 39.96 | ||
| 14-Day RSI | 72.21 | ||
| 14-Day ATR (€) | 0.165027 | ||
| 20-Day SMA (€) | 5.263 | ||
| 12-1 Month Momentum % | 50 | ||
| 52-Week Range (€) | 2.78 - 6.15 | ||
| Shares Outstanding (Mil) | 50.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genfit SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genfit SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-09-29 | In 83 days | ||
| General meeting for 2025 | 2026-06-15 | 5.55 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 5.55 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-02 | 5.55 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 3.62 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-22 | 3.80 (+7.34%) | ||
| General meeting for 2024 | 2025-06-17 10:00 | 3.48 (+0.00%) | ||
| Annual report for 2024 | 2025-04-29 | 3.12 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-24 | 2.92 (+0.00%) |
Show
Entries
Genfit SA Frequently Asked Questions
What is Genfit SA(FRA:XUPB)'s stock price today?
The current price of FRA:XUPB is €6.15. The 52 week high of FRA:XUPB is €6.15 and 52 week low is €2.78.
When is next earnings date of Genfit SA(FRA:XUPB)?
The next earnings date of Genfit SA(FRA:XUPB) is 2026-09-29.
Does Genfit SA(FRA:XUPB) pay dividends? If so, how much?
Genfit SA(FRA:XUPB) does not pay dividend.
Press Release
Articles on Genfit SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers